S eligible for analysis of predictive function of posttreatment metabolic response, the baseline SUV reported a mean of 12.60 (s.d..89). The imply SUV at the end of remedy was 3.80 (s.d..88), using a imply percentage reduction of 63.0 (s.d.two.eight; Po0.001, Wilcoxon rank sum test).Evaluation of potential biomarkers inside the plasmaIn all, 33 various proteins plasma levels were measured in 28 sufferers at baseline, at intermediate (week 8) and post-treatment evaluation (week 17). Table four describes, for every single cytokine analysed, median baseline values and median changes from baseline, week eight and at week 17. At intermediate and post-treatment evaluation, levels of several cytokines had been considerably different even after many comparison correction, with significance defined by local false discovery rate qo0.05, upper limit of regular. Nevertheless when these variations have been evaluated as outlined by response to remedy, there was no important difference among cytokine variation levels amongst responding and non-responding sufferers (Supplementary Material Figures 1 and 2).Table three Treatment-related SR-BI/CD36 Proteins Biological Activity toxicityG0 7 40 83 23 53 85 75 53 G1 13 23 12 45 35 ten 20 45 G2 50 7 five 32 12 five five two G3 30 20 0 0 0 0 0 0 G4 0 10 0 0 0 0 0Abbreviations: path CR pathological response price; path PR pathological partial response; RR response rate.100 80 60 40Toxicity0 0 Quantity at threat 41 6 12 18 Months 32 24 14 five two 1 24 30Figure 2 Kaplan Meier plots of overall survival. The median and imply overall survival time was 17.three and 16 months, respectively. The 12, 24 and 36 months general survival rates were: 67, 42, and 42 , respectively.British Journal of Cancer (2011) 104(3), 427 Skin Neutropenia Anemia Esophagitis Nausea/vomiting Diarrhea Stomatitis Neurotoxicity2011 Cancer Investigation UKMultimodality therapy for oesophageal cancer F De Vita et alTable 4 Cytokine worth at baseline, at week 7 and weekIntermediate Baseline median Baselinea 178.1 257.5 eight.9 38.8 1.0 39.eight 29.six NA 91 89 108 90 98 53 Post-treatmentCytokine Development elements VEGF HGF FGFb PlGF Epiregulin TGFa EGF Chemokines Eotaxin IL eight IP 10 MCP 1 MIG MIP-1A MIP-1B RANTES Haemopoietins G-CSF GM-CSF IL 2 IL 2R IL 4 IL 5 IL 6 IL 7 IL 13 ILP NA 0.1479 0.0448 0.927 0.4807 0.9933 0.Baselinea 120 62 80 91 78 108P 0.5891 0.0493 o0.0001b 0.915 0.6824 0.3316 0.444 0.0001b 0.1772 0.0084b 0.0652b 0.0159b o0.0001b o0.0001b 0.045 0.0159b o0.0001b 0.0201b 0.129 o0.0001b o0.0001b 0.0003b o0.0001b 1 o0.0001b o0.0001b o0.0001b o0.0001b o0.0001b 0.0002b o0.0001b o0.0001b 0.0044b56.0 3.five 8.0 175.5 15.2 39.7 47.2 5696.81 92 148 76 88 58 580.4527 0.4282 0.0029b 0.3629 0.3598 o0.0001b 0.0112b 0.0724 0.0014b 0.0135b 0.2637 0.467 0.0003b 0.2881 0.0164b 0.0001b 0.5558 0.0049b33 72 151 67 61 37 3959.1 19.three 1.four 194.2 27.5 14.1 2.3 11.0 7.two 13.80 one hundred 99 85 49 41.3 136 142 10081 103 82 84 43 12 142 175 100Other molecules IFNa 20.7 IFNg 52.6 TNF-A 7.3 IL 1b 13.3 IL 1Ra 373.1 IL ten 1.8 IL 12 185.1 IL 17 13.88 52 49 69 46 183 420.3498 o0.0001b o0.0001b 0.0008b 0.0002b 0.001b o0.0001b 0.67 35 48 57 52 315 21Abbreviations: EGF ROR family Proteins site epidermal development issue; FGF fibroblast growth aspect; G-CSF granulocyte colony-stimulating issue; GM-CSF granulocyte macrophage colony-stimulating issue; HGF hepatocyte growth issue; IL interleukin; INF interferon; IP inducible protein; MCP monocyte chemoattractant protein; MIG monokine induced by gamma interferon; MIP macrophage inflammatory proteins; NA not available; PlGF placenta development aspect; RANTES regulated on activation standard.